The Novel HDAC Inhibitor OBP-801 Promotes MHC Class I Presentation Through LMP2 Upregulation, Enhancing the PD-1-Targeting Therapy in Clear Cell Renal Cell Carcinoma
Our results demonstrate that OBP-801 promotes MHC class I presentation through LMP2 upregulation in tumor cells and thereby potentiates PD-1-targeting therapy. These data suggest that the combination of OBP-801 and anti-PD-1 treatment is a promising therapeutic strategy for ccRCC.
Authors
- Osamu Ukimura (ORCID: https://orcid.org/0000-0003-3443-3210)
- Takahiro Tsujikawa (ORCID: https://orcid.org/0000-0003-1647-342X)
- Keiko Taniguchi
- Tsukasa Narukawa
- Mano Horinaka (ORCID: https://orcid.org/0000-0001-8168-1802)
- Shusuke Yasuda (ORCID: https://orcid.org/0009-0001-5978-3199)
- Mie Morita
- Toshiyuki Sakai
Institutions
- Kyoto Prefectural University of Medicine (JP)
Publication Details
- Journal
- Cancers
- Published
- 2024-12-04
- DOI
- https://doi.org/10.3390/cancers16234058
- Citations
- 9
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- Japan Agency for Medical Research and Development